Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: Applications in diabetes and cancer

Fundamental and Clinical Pharmacology

Volumn 18, Issue 4, 2004, Pages 413-422

  Chapal, Nicolas ^a   Molina, Laurence ^b   Molina, Franck ^b   Laplanche, Marion ^a   Pau, Bernard ^b   Petit, Pierre ^b  

^a INNODIA SAS   (France)

^b CNRS   (France)

Author keywords

Bioinformatics; Cancer; Diabetes; Mass spectrometry; Pharmacoproteomics; Proteomics; Two dimensional gel electrophoresis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; A 204197; ANTIDIABETIC AGENT; ANTIMITOTIC AGENT; CISPLATIN; CLOFIBRIC ACID; DAUNORUBICIN; DOXORUBICIN; ETOMOXIR; ETOPOSIDE; MITOXANTRONE; NAFENOPIN; ORAL ANTIDIABETIC AGENT; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PIRINIXIC ACID; PROTEIN KINASE C; ROSIGLITAZONE; SDZ PUG 693; THIOREDOXIN; TOMELUKAST; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; BIOINFORMATICS; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; COMPUTER PROGRAM; CYTOSKELETON; DRUG MECHANISM; HUMAN; MULTIDRUG RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOPROTEOMIC; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; HUMANS; HYPOGLYCEMIC AGENTS; NEOPLASMS; PROTEOMICS; TUMOR CELLS, CULTURED;

EID: 4544306096     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2004.00258.x     Document Type: Review

References (59)

1. Wasinger V.C., Cordwell S.J., Cerpa-Poljak A. et al. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis (1995) 16 1090-1094.
2. Pandey A., Mann M. Proteomics to study genes and genomes. Nature (2000) 405 837-846.
3. Naaby-Hansen S., Waterfield M.D., Cramer R. Proteomics - post-genomic cartography to understand gene function. Trends Pharmacol. Sci. (2001) 22 376-384.
4. Sanchez J.C., Chiappe D., Converset V. et al. The mouse SWISS-20 PAGE database: a tool for proteomics study of diabetes and obesity. Proteomics (2001) 1 136-163.
5. Gromov P.S., Ostergaard M., Gromova I., Celis J.E. Human proteomic databases: a powerful resource for functional genomics in health and disease. Prog. Biophys. Mol. Biol. (2002) 80 3-22.
6. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature (2001) 414 782-787.
7. Andersen H.U., Larsen P.M., Fey S.J., Karlsen A.E., Mandrup-Poulsen T., Nerup J. Two-dimensional gel electrophoresis of rat islet proteins. Interleukin 1 beta-induced changes in protein expression are reduced by L-arginine depletion and nicotinamide. Diabetes (1995) 44 400-407.
8. Andersen H.U., Fey S.J., Larsen P.M. et al. Interleukin-1beta induced changes in the protein expression of rat islets: a computerized database. Electrophoresis (1997) 18 2091-2103.
9. John N.E., Andersen H.U., Fey S.J. et al. Cytokine- or chemically derived nitric oxide alters the expression of proteins detected by two-dimensional gel electrophoresis in neonatal rat islets of Langerhans. Diabetes (2000) 49 1819-1829.
10. Larsen P.M., Fey S.J., Larsen M.R. et al. Proteome analysis of interleukin-1beta-induced changes in protein expression in rat islets of Langerhans. Diabetes (2001) 50 1056-1063.
11. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature (2001) 414 821-827.
12. Lanne B., Potthast F., Hoglund A. et al. Thiourea enhances mapping of the proteome from murine white adipose tissue. Proteomics (2001) 1 819-828.
13. Yan J.X., Harry R.A., Wait R. et al. Separation and identification of rat skeletal muscle proteins using two-dimensional gel electrophoresis and mass spectrometry. Proteomics (2001) 1 424-434.
14. Fountoulakis M., Berndt P., Boelsterli U.A. et al. Two-dimensional database of mouse liver proteins: changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis (2000) 21 2148-2161.
15. Fountoulakis M., Juranville J.F., Berndt P., Langen H., Suter L. Two-dimensional database of mouse liver proteins. An update. Electrophoresis (2001) 22 1747-1763.
16. Fountoulakis M., Berndt P., Langen H., Suter L. The rat liver mitochondrial proteins. Electrophoresis (2002) 23 311-328.
17. Lopez M.F., Kristal B.S., Chernokalskaya E. et al. High-throughput profiling of the mitochondrial proteome using affinity fractionation and automation. Electrophoresis (2000) 21 3427-3440.
18. Taylor R.S., Wu C.C., Hays L.G., Eng J.K., Yates J.R. III, Howell K.E. Proteomics of rat liver Golgi complex: minor proteins are identified through sequential fractionation. Electrophoresis (2000) 21 3441-3459.
19. Hochstrasser D.F., Frutiger S., Paquet N. et al. Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis (1992) 13 992-1001.
20. Hughes G.J., Frutiger S., Paquet N. et al. Human liver protein map: update 1993. Electrophoresis (1993) 14 1216-1222.
21. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev. (2002) 18 S10-S15.
22. Anderson N.L., Esquer-Blasco R., Richardson F., Foxworthy P., Eacho P. The effects of peroxisome proliferators on protein abundances in mouse liver. Toxicol. Appl. Pharmacol. (1996) 137 75-89.
23. Edvardsson U., Alexandersson M., Brockenhuus von Lowenhielm H. et al. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643. Electrophoresis (1999) 20 935-942.
24. Edvardsson U., Brockenhuus Von Lowenhielm H., Panfilov O., Nystrom A.C., Nilsson F., Dahllof B. Hepatic protein expression of lean mice and obese diabetic mice treated with peroxisome proliferator-activated receptor activators. Proteomics (2003) 3 468-478.
25. Sanchez J.C., Converset V., Nolan A. et al. Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57B1/6 lep/lep mice. Mol. Cell. Proteomics (2002) 1 509-516.
26. Sanchez J.C., Converset V., Nolan A. et al. Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. Proteomics (2003) 3 1500-1520.
27. Bandara L.R., Kennedy S. Toxicoproteomics: a new preclinical tool. Drug Discov. Today (2002) 7 411-418.
28. Kennedy S. The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers (2002) 7 269-290.
29. Steiner S., Wahl D., Mangold B.L. et al. Induction of the adipose differentiation-related protein in liver of etomoxir-treated rats. Biochem. Biophys. Res. Commun. (1996) 218 777-782.
30. Arce A., Aicher L., Wahl D. et al. Changes in the liver protein pattern of female Wistar rats treated with the hypoglycemic agent SDZ PGU 693. Life Sci. (1998) 63 2243-2250.
31. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer (2002) 2 48-58.
32. Hutter G., Sinha P. Proteomics for studying cancer cells and the development of chemoresistance. Proteomics (2001) 1 1233-1248.
33. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. (2002) 53 615-627.
34. Volm M., Pommerenke E.W. Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer. Anticancer Res. (1995) 15 463-466.
35. Kavallaris M., Tait A.S., Walsh B.J. et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. (2001) 61 5803-5809.
36. Sinha P., Hutter G., Kottgen E., Dietel M., Schadendorf D., Lage H. Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 20 2952-2960.
37. Moller A., Malerczyk C., Volker U., Stoppler H., Maser E. Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis. Proteomics (2002) 2 697-705.
38. Sinha P., Kohl S., Fischer J. et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 21 3048-3057.
39. Sinha P., Hutter G., Kottgen E., Dietel M., Schadendorf D., Lage H. Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J. Biochem. Biophys. Methods (1998) 37 105-116.
40. Cole S.P., Pinkoski M.J., Bhardwaj G., Deeley R.G. Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br. J. Cancer (1992) 65 498-502.
41. Sinha P., Hutter G., Kottgen E., Dietel M., Schadendorf D., Lage H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis (1999) 20 2961-2969.
42. Yokomizo A., Ono M., Nanri H. et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. (1995) 55 4293-4296.
43. Huang J., Sweet P., Slater L.M., Sartorelli A.C., Leung M.F. Microtubule-dependent multilobular organization of the nucleus in sensitive and multidrug-resistant L0 leukemia cells. Cancer Lett. (1996) 106 29-41.
44. Han E.K., Tahir S.K., Cherian S.P., Collins N., Ng S.C. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br. J. Cancer (2000) 83 83-88.
45. Fine R.L., Patel J., Chabner B.A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. (1988) 85 582-586.
46. Basu A., Weixel K., Saijo N. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Cell Growth Differ. (1996) 7 1507-1512.
47. Dellambra E., Patrone M., Sparatore B. et al. Stratifin, a keratinocyte specific 14-3-3 protein, harbors a pleckstrin homology (PH) domain and enhances protein kinase C activity. J. Cell Sci. (1995) 108 3569-3579.
48. Takeuchi N., Nakamura T., Takeuchi F., Hashimoto E., Yamamura H. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J. Biochem. (Tokyo) (1992) 112 762-767.
49. Carollo M., Parente L., D'Alessandro N. Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1. Oncol. Res. (1998) 10 245-254.
50. Wu Y.L., Jiang X.R., Lillington D.M., Newland A.C., Kelsey S.M. Upregulation of lipocortin 1 inhibits tumour necrosis factor-induced apoptosis in human leukaemic cells: a possible mechanism of resistance to immune surveillance. Br. J. Haematol. (2000) 111 807-816.
51. Slater L.M., Sweet P., Hsu T.C., Chan P.K. Novel nucleolar and nuclear morphology in a vincristine-dependent human leukemia cell line (L100). Exp. Cell Res. (1992) 198 170-174.
52. Poruchynsky M.S., Giannakakou P., Ward Y. et al. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem. Pharmacol. (2001) 62 1469-1480.
53. Sangrajrang S., Calvo F., Fellous A. Estramustine resistance. Gen. Pharmacol. (1999) 33 107-113.
54. Poland J., Sinha P., Siegert A., Schnolzer M., Korf U., Hauptmann S. Comparison of protein expression profiles between monolayer and spheroid cell culture of HT-29 cells revealed fragmentation of CK18 in three-dimensional cell culture. Electrophoresis (2002) 23 1174-1184.
55. Protein Science Benchmarking Study. December 2001. http://www.biofind. com/business/reports/1benchmarking.pdf.
56. Ge H., Walhout A.J., Vidal M. Integrating 'omic' information: a bridge between genomics and systems biology. Trends Genet. (2003) 19 551-560.
57. Taylor C.F., Paton N.W., Garwood K.L. et al. A systematic approach to modeling, capturing, and disseminating proteomics experimental data. Nat. Biotechnol. (2003) 21 247-254.
58. Kitano H. Computational systems biology. Nature (2002) 420 206-210.
59. Takahashi K., Ishikawa N., Sadamoto Y. et al. E-Cell 2: Multi-platform E-Cell simulation system. Bioinformatics (2003) 19 1727-1729.